Kancera Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
KAN
- Investments
-
2
- Share Price
-
$0.12
- (As of Wednesday Closing)
Kancera General Information
Description
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.
Contact Information
Website
www.kancera.comCorporate Office
- Nanna Svartz Väg 4
- 171 65 Solna
- Sweden
Corporate Office
- Nanna Svartz Väg 4
- 171 65 Solna
- Sweden
Kancera Stock Performance
As of 26-Mar-2025, Kancera’s stock price is $0.12. Its current market cap is $14.5M with 121M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.12 | $0.12 | $0.07 - $0.29 | $14.5M | 121M | 222K | -$0.04 |
Kancera Financials Summary
As of 31-Dec-2024, Kancera has a trailing 12-month revenue of $1.32K.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 6,274 | 6,274 | 31,741 | 10,064 |
| Revenue | 1 | 1 | 97 | 74 |
| EBITDA | (4,365) | (4,365) | (5,837) | (5,133) |
| Net Income | (4,214) | (4,214) | (6,105) | (5,173) |
| Total Assets | 6,015 | 6,015 | 6,568 | 11,574 |
| Total Debt | 0 | 0 | 0 | 0 |
Kancera Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kancera Comparisons
Industry
Financing
Details
Kancera Competitors (3)
One of Kancera’s 3 competitors is Botanix Pharmaceuticals, a Corporation company based in West Perth, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Botanix Pharmaceuticals | Corporation | West Perth, Australia | ||||
| Clinuvel Pharmaceuticals | Corporation | Melbourne, Australia | ||||
| Audion Therapeutics | Venture Capital-Backed | Amsterdam, Netherlands |
Kancera Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kancera Patents
Kancera Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202401289-D0 | New use | Pending | 31-Jan-2024 | ||
| GB-202319559-D0 | New use | Pending | 19-Dec-2023 | ||
| GB-202006849-D0 | New use | Inactive | 08-May-2020 | ||
| EP-3818065-B1 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1 | Active | 06-Jul-2018 | ||
| EP-3818065-A1 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1 | Active | 06-Jul-2018 | C07F9/6561 |
Kancera Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kancera Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Kancera Investments & Acquisitions (2)
Kancera’s most recent deal was a Corporate Asset Purchase with AstraZeneca and Acturum Real Estate (Rights of KAND567 Fractalkine Project). The deal was made on 11-Dec-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AstraZeneca and Acturum Real Estate (Rights of KAND567 Fractalkine Project) | 11-Dec-2017 | Corporate Asset Purchase | Buildings and Property | ||
| iNovacia | 17-Feb-2011 | Merger/Acquisition | Drug Discovery |
Kancera ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Kancera FAQs
-
When was Kancera founded?
Kancera was founded in 2010.
-
Where is Kancera headquartered?
Kancera is headquartered in Solna, Sweden.
-
What is the size of Kancera?
Kancera has 5 total employees.
-
What industry is Kancera in?
Kancera’s primary industry is Biotechnology.
-
Is Kancera a private or public company?
Kancera is a Public company.
-
What is Kancera’s stock symbol?
The ticker symbol for Kancera is KAN.
-
What is the current stock price of Kancera?
As of 26-Mar-2025 the stock price of Kancera is $0.12.
-
What is the current market cap of Kancera?
The current market capitalization of Kancera is $14.5M.
-
What is Kancera’s current revenue?
The trailing twelve month revenue for Kancera is $1.32K.
-
Who are Kancera’s competitors?
Botanix Pharmaceuticals, Clinuvel Pharmaceuticals, and Audion Therapeutics are competitors of Kancera.
-
What is Kancera’s annual earnings per share (EPS)?
Kancera’s EPS for 12 months was -$0.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
